Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys

Journal of Bone and Mineral Research

Volumn 29, Issue 8, 2014, Pages 1847-1858

  Pennypacker, Brenda L ^a   Chen, Charles M ^a   Zheng, Helen ^b   Shih, Mei Shu ^b   Belfast, Mary ^a   Samadfam, Rana ^c   Duong, Le T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PharmaLegacy Laboratories   (China)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Bone Formation; Cathepsin K Inhibitor; Cortical Bone; Modeling; Nonhuman Primate; Osteoclast; Osteoporosis; Ovariectomy; Remodeling

Indexed keywords

CALCEIN; ODANACATIB; TETRACYCLINE; BIPHENYL DERIVATIVE; CATHEPSIN K;

ARTICLE; BONE MINERAL; BONE STRENGTH; CORTICAL BONE; CORTICAL THICKNESS (BONE); CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; OVARIECTOMY; PERIOSTEUM; RHESUS MONKEY; THERAPY EFFECT; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DENSITY; BONE DEVELOPMENT; BONE REMODELING; DRUG EFFECTS; HIP; PATHOLOGY; SPINE;

ANIMALS; BIPHENYL COMPOUNDS; BONE DENSITY; BONE REMODELING; CATHEPSIN K; FEMALE; HIP; MACACA MULATTA; OSTEOGENESIS; OVARIECTOMY; SPINE;

EID: 84904620328     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2211     Document Type: Article

References (41)

1. Frost HM., Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff's law: the bone modeling problem. Anat Rec. 1990; 226 (4): 403-13.
2. Seeman E., Pathogenesis of bone fragility in women and men. Lancet. 2002; 359 (9320): 1841-50.
3. Jee WS, Tian XY, Setterberg RB., Cancellous bone minimodeling-based formation: a Frost, Takahashi legacy. J Musculoskelet Neuronal Interact. 2007; 7 (3): 232-9.
4. Erben RG., Trabecular and endocortical bone surfaces in the rat: modeling or remodeling ? Anat Rec. 1996; 246 (1): 39-46.
5. Baron R, Ferrari S, Russell RG., Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011; 48 (4): 677-92.
6. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344 (19): 1434-41.
7. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005; 20 (7): 1244-53.
8. Hock JM, Hummert JR, Boyce R, Fonseca J, Raisz LG., Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J Bone Miner Res. 1989; 4 (3): 449-58.
9. Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21 (6): 855-64.
10. Duong LT., Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep. 2012; 1: 67.
11. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008; 18 (3): 923-8.
12. Pennypacker BL, Duong le T, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner.Res. 2011 Feb; 26 (2): 252-62.
13. Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012 Mar; 27 (3): 509-23.
14. Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone. 2007; 40 (1): 122-31.
15. Jerome C, Missbach M, Gamse R., Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int. 2012; 23 (1): 339-49.
16. Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012; 27 (3): 524-37.
17. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28 (1): 2-17.
18. Seeman E., From density to structure: growing up and growing old on the surfaces of bone. J Bone Miner Res. 1997; 12 (4): 509-21.
19. Seeman E, Delmas PD., Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354 (21): 2250-61.
20. Fleisch H., Bisphosphonates in bone disease-from the laboratory to the patient. New York: Academic Press; 2000.
21. Szulc P, Seeman E, Duboeuf F, Sornay-Rendu E, Delmas PD., Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res. 2006; 21 (12): 1856-63.
22. Thomas CD, Feik SA, Clement JG., Regional variation of intracortical porosity in the midshaft of the human femur: age and sex differences. J Anat. 2005; 206 (2): 115-25.
23. Wall JC, Chatterji SK, Jeffery JW., Age-related changes in the density and tensile strength of human femoral cortical bone. Calcif Tissue Int. 1979; 27 (2): 105-8.
24. Pearson OM, Lieberman DE., The aging of Wolff's "law": ontogeny and responses to mechanical loading in cortical bone. Am J Phys Anthropol. 2004; 125 (Suppl 39): 63-99.
25. Napoli N, Jin J, Peters K, et al. Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. J Clin Endocrinol Metab. 2012; 97 (7): 2414-22.
26. Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T., Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. Bone. 2013; 54 (1): 1-7.
27. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS., Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011; 49 (2): 151-61.
28. Ominsky MS, Stouch B, Schroeder J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011; 49 (2): 162-73.
29. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R., Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 2001; 28 (2): 150-9.
30. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM., Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001; 16 (1): 157-65.
31. Sato M, Westmore M, Ma YL, et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res. 2004; 19 (4): 623-9.
32. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY., Effects of daily treatment with parathyroid hormone. 1-84. for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007; 41 (3): 321-30.
33. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ., Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100 (6): 1475-80.
34. Eriksen EF, Melsen F, Sod E, Barton I, Chines A., Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002; 31 (5): 620-5.
35. Chen C, Shih M, Zheng H, Duong LT., Odanacatib treatment reduces remodeling and stimulates modeling-based bone formation in central femur and lumbar vertebra of adult OVX monkeys. JBMR. 2012; 27 Suppl 1. [Presented at: Annual Meeting American Society for Bone and Mineral Research (ASBMR); 2012 Oct 12-15; Minneapolis, MN, USA; Presentation Number: FR0420]. Available from: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= a6fac4d7-544e-4000-8ecc-5e42c5aed376.
36. Dempster DW, Cosman F, Kurland ES, et al., Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16 (10): 1846-53.
37. Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006; 21 (3): 366-73.
38. Leung P, Pickarski M, Zhuo Y, Masarachia PJ, Duong LT., The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone. 2011; 49 (4): 623-35.
39. Stroup G, Kumar S, Jerome C., Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int. 2009; 85 (4): 344-55.
40. Fratzl-Zelman N, Roschger P, Fisher JE, Duong le T, Klaushofer K., Effects of odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study. Calcif Tissue Int. 2013; 92 (3): 261-9.
41. Turner CH., Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int. 2002; 13 (2): 97-104.